MedTrace Logo

Benefit and Tolerability of IQP-AE-103 in Weight Loss

NCT03058367 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 108

Last updated 2018-01-03

No results posted yet for this study

Summary

This study is to evaluate the benefit and tolerability of two dosages of IQP-AE-103 (990mg and 1980mg daily) in reducing body weight in overweight and moderately obese subjects

Conditions

Interventions

DIETARY_SUPPLEMENT

IQP-AE-103 (330mg)

High dose capsules

DIETARY_SUPPLEMENT

IQP-AE-103 (165mg)

Low dose capsules

DIETARY_SUPPLEMENT

Placebo

Placebo identical to verum capsules

Sponsors & Collaborators

  • InQpharm Group

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-05-01
Primary Completion
2017-11-28
Completion
2017-11-28

Countries

  • Germany

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03058367 on ClinicalTrials.gov